Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: are we aware of the therapeutic impact of intratumor heterogeneity?

Related Articles

Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: are we aware of the therapeutic impact of intratumor heterogeneity?

Cancer Biol Ther. 2018 Mar 26;:1-13

Authors: Baretti M, Personeni N, Destro A, Santoro A, Rimassa L

Abstract
Tumors represent a dynamic system where the genomic plasticity permits to adapt to the perturbation induced by environmental pressures, supporting the importance of longitudinal tumor sampling strategies to deciphering the temporal acquisition of driver event that could impact treatment outcome. We describe the case of a metastatic colorectal cancer (mCRC) patient, RAS wild-type, who responded to anti-EGFR therapy and underwent liver surgery, revealing a KRAS mutations in the metastatic lesion, not detectable prior to initiation of therapy in the colonic biopsy. After liver surgery, the patient received chemotherapy alone, then underwent left colectomy and the final pathological report confirmed the KRAS wild-type status. We can speculate the existence of two distinct populations of KRAS wild-type and mutant CRC cells sharing the same genetic origin. The anti-EGFR treatment represented a selective pressure which allowed the selection of KRAS mutant subclones. The prognostic and /or predictive role of intratumor heterogeneity has not been assessed prospectively. Our case report is of clinical relevance because patients with mCRC who respond to anti-EGFR antibodies often develop resistance within several months of initiating therapy, thus outlining the importance to better ascertain the molecular landscape of tumors to design better therapeutic strategies.</p>.

PMID: 29580164 [PubMed - as supplied by publisher]

from #ORL-AlexandrosSfakianakis via ola Kala on Inoreader https://ift.tt/2uwH58m